Steep rise in drug use-associated infective endocarditis in West Virginia: Characteristics and healthcare utilization

Introduction Life-threatening infections such as infective endocarditis (IE) are increasing simultaneously with the injection drug use epidemic in West Virginia (WV). We utilized a newly developed, statewide database to describe epidemiologic characteristics and healthcare utilization among patients with (DU-IE) and without (non-DU-IE) drug use-associated IE in WV over five years. Materials and methods This retrospective, observational study, incorporating manual review of electronic medical records, included all patients aged 18–90 years who had their first admission for IE in any of the four university-affiliated referral hospitals in WV during 2014–2018. IE was identified using ICD-10-CM codes and confirmed by chart review. Demographics, clinical characteristics, and healthcare utilization were compared between patients with DU-IE and non-DU-IE using Chi-square/Fisher’s exact test or Wilcoxon rank sum test. Multivariable logistic regression analysis was conducted with discharge against medical advice/in-hospital mortality vs. discharge alive as the outcome variable and drug use as the predictor variable. Results Overall 780 unique patients had confirmed first IE admission, with a six-fold increase during study period (p = .004). Most patients (70.9%) had used drugs before hospital admission, primarily by injection. Compared to patients with non-DU-IE, patients with DU-IE were significantly younger (median age: 33.9 vs. 64.1 years; p < .001); were hospitalized longer (median: 25.5 vs. 15 days; p < .001); had a higher proportion of methicillin-resistant Staphylococcus aureus (MRSA) isolates (42.7% vs. 29.9%; p < .001), psychiatric disorders (51.2% vs. 17.3%; p < .001), cardiac surgeries (42.9% vs. 26.6%; p < .001), and discharges against medical advice (19.9% vs. 1.4%; p < .001). Multivariable regression analysis showed drug use was an independent predictor of the combined outcome of discharge against medical advice/in-hospital mortality (OR: 2.99; 95% CI: 1.67–5.64). Discussion and conclusion This multisite study reveals a 681% increase in IE admissions in WV over five years primarily attributable to injection drug use, underscoring the urgent need for both prevention efforts and specialized strategies to improve outcomes.

[1]  L. Baddour,et al.  Injection Drug Use: A Minor Criterion With Major Implications for Patients With Infective Endocarditis. , 2021, Journal of the American College of Cardiology.

[2]  M. Hannan,et al.  Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs. , 2021, Journal of the American College of Cardiology.

[3]  I. Olivotto,et al.  Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre , 2021, BMC Cardiovascular Disorders.

[4]  H. Englander,et al.  Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018 , 2020, PloS one.

[5]  H. Englander,et al.  Long-term infective endocarditis mortality associated with injection opioid use in the United States: a modeling study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Liang,et al.  Use of ICD-10 Codes for Identification of Injection Drug Use–Associated Infective Endocarditis Is Nonspecific and Obscures Critical Findings on Impact of Medications for Opioid Use Disorder , 2020, Open forum infectious diseases.

[7]  June-Ho Kim,et al.  Against medical advice discharges in injection and non-injection drug use-associated infective endocarditis: A nationwide cohort study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Mori,et al.  Trends in Infective Endocarditis Hospitalizations, Characteristics, and Valve Operations in Patients With Opioid Use Disorders in the United States: 2005–2014 , 2020, Journal of the American Heart Association.

[9]  M. Kainer,et al.  Methicillin-Resistant Staphylococcus aureus Bloodstream Infections and Injection Drug Use, Tennessee, USA, 2015–2017 , 2020, Emerging infectious diseases.

[10]  K. Thakarar,et al.  Rural–Urban Differences in Hospitalizations for Opioid Use–Associated Infective Endocarditis in the United States, 2003–2016 , 2020, Open forum infectious diseases.

[11]  M. Stein,et al.  Outcomes Associated with Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Slaughter,et al.  The opioid epidemic and intravenous drug-associated endocarditis: A path forward. , 2020, The Journal of thoracic and cardiovascular surgery.

[13]  Mylan C. Cohen,et al.  Mortality, morbidity, and cardiac surgery in Injection Drug Use (IDU)-associated versus non-IDU infective endocarditis: The need to expand substance use disorder treatment and harm reduction services , 2019, PloS one.

[14]  D. Grande,et al.  Changes in infective endocarditis admissions in Pennsylvania during the opioid epidemic. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Kapadia,et al.  Geographic Trends, Patient Characteristics, and Outcomes of Infective Endocarditis Associated With Drug Abuse in the United States From 2002 to 2016 , 2019, Journal of the American Heart Association.

[16]  M. Alkhouli,et al.  Contemporary trends and outcomes of mitral valve surgery for infective endocarditis , 2019, Journal of cardiac surgery.

[17]  B. Stein,et al.  The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia. , 2019, Health affairs.

[18]  M. Bates,et al.  Increasing incidence of IV‐drug use associated endocarditis in southern West Virginia and potential economic impact , 2019, Clinical cardiology.

[19]  P. Benharash,et al.  Clinical Outcomes of Infective Endocarditis in Injection Drug Users. , 2019, Journal of the American College of Cardiology.

[20]  A. Fleischauer,et al.  Trends in Drug UseAssociated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017 , 2018, Annals of Internal Medicine.

[21]  D. Warren,et al.  Addiction Medicine Consultations Reduce Readmission Rates for Patients With Serious Infections From Opioid Use Disorder. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Silverman,et al.  Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs , 2018, JAMA network open.

[23]  R. Dillingham,et al.  Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study , 2018, BMC Infectious Diseases.

[24]  Sadeer G. Al-Kindi,et al.  Changes in the Association of Rising Infective Endocarditis With Mortality in People Who Inject Drugs , 2018, JAMA cardiology.

[25]  W. Schaffner,et al.  Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[26]  M. Khan,et al.  Admissions for Infective Endocarditis in Intravenous Drug Users. , 2018, Journal of the American College of Cardiology.

[27]  J. Feinberg,et al.  Endocarditis as a Marker for New Epidemics of Injection Drug Use , 2016, The American journal of the medical sciences.

[28]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[29]  Joanne E Brady,et al.  Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.